Key result
Interferon alpha 2a yields dose-dependent antiviral effects, avoiding clinical side effects at the lowest dose.
Why the study?
The kinetics of the antiviral effect of recombinant human interferon alpha 2a by different doses and routes in healthy volunteers were not fully characterized.
Does recombinant human interferon alpha 2a dose and route of administration affect antiviral response in healthy volunteers?
Cohort
Does recombinant human interferon alpha 2a dose and route of administration affect antiviral response in healthy volunteers?
Recombinant human interferon alpha 2a demonstrates a dose-dependent antiviral effect in healthy volunteers, which can occur without clinical side effects at lower doses.
May inform low-dose strategies to minimize side effects; leaves open clinical efficacy and optimal use in patients.
The kinetics of the antiviral effect of intramuscular and intravenous injections of recombinant human interferon alpha 2a were investigated in healthy volunteers. Cohorts of eight to 11 subjects received single intramuscular injections of either 0.3 X 10(6), 3 X 10(6), or 18 X 10(6) U or an intravenous infusion of 18 X 10(6) U over 30 minutes. Serial samples of peripheral blood mononuclear cells were analyzed for antiviral effects including both (2'-5') oligoadenylate synthetase activity and resistance to vesicular stomatitis virus infection in vitro. A dose-response relationship was established between recombinant human interferon alpha 2a dose and both vesicular stomatitis virus resistance and (2'-5') oligoadenylate synthetase activity. At the 0.3 X 10(6) U dose an antiviral effect occurred without clinical side effects. The presence of clinical side effects is not necessary for an antiviral effect.
No takes yet. Share an insight, caveat, or question.
Witter et al. (1987) conducted a cohort in Healthy volunteers. Recombinant human interferon alpha 2a was evaluated on Antiviral effects including (2'-5') oligoadenylate synthetase activity and resistance to vesicular stomatitis virus infection in vitro. Recombinant human interferon alpha 2a demonstrated a dose-response relationship for antiviral effects, with the lowest dose (0.3 x 10^6 U) producing an antiviral effect without clinical side effects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: